Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma
https://doi.org/10.30895/2221-996X-2018-18-3-184-190
Abstract
Methods used to control the quality of peptide products depend on the level of development of analytical and bioorganic chemistry, and the level of instrumentation. Peptide identification is a difficult task and largely depends on the complexity of its structure. There does not exist a comprehensive and simple test, except for NMR, which, however, is rather expensive and time-consuming and involves complex data interpretations. Moreover, it does not allow for unambiguous determination of the peptide purity and formula (amino acid composition, sequence, chirality of amino acid residues). For this reason, a combination of methods is often used, including amino acid analysis, TLC/HPLC and mass spectrometry, and, less frequently, sequencing. Current international practice of peptide analysis is to use HPLC in combination with mass spectrometric, mainly tandem (HPLC-MS/MS), detection. According to literature sources the amino acid sequence of linear peptides can be analysed using various enzymes and subsequent identification of proteolysis products by mass spectrometry. This article presents approaches to the development of test methods for analysis of purity and identification testing of a small interfering RNA-based novel medicinal product, which will help standardise and control the quality of the production process.
Keywords
About the Authors
L. M. KrasnykhRussian Federation
Candidate of Biological Sciences, Head of the Department of Clinical Pharmacokinetics of the Clinical Pharmacology Centre of the FSBI «SCEEMP» of the Ministry of Health of Russia
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
V. V. Smirnov
Russian Federation
Candidate of Pharmaceutical Sciences, Leading Analyst of the Department of Clinical Pharmacokinetics of the Clinical Pharmacology Centre of the FSBI «SCEEMP» of the Ministry of Health of Russia; Head of LaboratoryNo. 73 for Clinical Pharmacology of the FSBI NRC Institute of Immunology FMBA of Russia
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
24 Kashirskoe highway, Moscow 115478, Russian Federation
G. V. Ramenskaya
Russian Federation
Doctor of Pharmaceutical Sciences, Leading Analyst of the Department of Drug Interactions and Rational Pharmacotherapy of the Clinical Pharmacology Centre of the FSBI «SCEEMP» of the Ministry of Health of Russia
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
G. F. Vasilenko
Russian Federation
Candidate of Biological Sciences, Leading Research Associate of the Department of Clinical Pharmacokinetics of the Clinical Pharmacology Centre of the FSBI «SCEEMP» of the Ministry of Health of Russia
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
I. P. Shilovsky
Russian Federation
Doctor of Biological Sciences, Head of Laboratory No. 75 for Antiviral Immunity of the FSBI NRC Institute of Immunology FMBA of Russia
24 Kashirskoe highway, Moscow 115478, Russian Federation
M. R. Haitov
Russian Federation
Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Director of the FSBI NRC Institute of Immunology FMBA of Russia
24 Kashirskoe highway, Moscow 115478, Russian Federation
References
1. Whangbo JS, Hunter CP. Environmental RNA interfer- ence. Trends Genet. 2008;24(6):297–305. https://doi. org/10.1016/j.tig.2008.03.007
2. Rosenthal JJ. The emerging role of RNA editing in plas- ticity. J Exp Biol. 2015;218(Pt 12):1812–21. https://doi. org/10.1242/jeb.119065
3. Шиловский ИП, Мазуров ДВ, Шершакова НН, Гасанов ВА, Хаитов МР. Синтетические siRNA эффективно подавляют экспрессию провоспалительного цитокина интерлейкина-4 мыши in vitro. Иммунология. 2012;2:66–70. [Shilovskiy IP, Mazurov DV, Shershakova NN, Gasanov VA, Khaitov MR. siRNA suppresses the expression of murine proinflammatory interleukine-4 in vitro. Immunologiya = Immunology. 2012;2:66–70 (In Russ.)]
4. Khaitov MR, Shilovskiy IP, Nikonova AA, Shershakova NN, Kamyshnikov OY, Babakhin AA, et al. Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum Gene Ther. 2014;25(7):642–50. https://doi.org/10.1089/hum.2013.142
5. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343–9. https://doi.org/10.1038/nature02873
6. Manjila SB, Baby JN, Bijin EN, Constantine I, Pramod K, Valsalakumari J. Novel gene delivery systems. Int J Pharm Investig. 2013;3(1):1–7. https://doi.org/10.4103/2230-973X.108958
7. Кутин АА, Мастеркова ТВ, Яшкир ВА, Меркулов ВА, Ваганова ОА. Хромато-масс-спектрометрия: использование для идентификации лекарственных субстанций и примесей. Ведомости Научного центра экспертизы средств медицинского применения. 2013;(2):12–4. [Kutin AA, Masterkova TV, Yashkir VA, Merkulov VA, Vaganova OA. UPLC/MS/MS method for identification of drug substances and impurities. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2013;(2):12–4 (In Russ.)]
Review
For citations:
Krasnykh L.M., Smirnov V.V., Ramenskaya G.V., Vasilenko G.F., Shilovsky I.P., Haitov M.R. Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma. BIOpreparations. Prevention, Diagnosis, Treatment. 2018;18(3):184-190. (In Russ.) https://doi.org/10.30895/2221-996X-2018-18-3-184-190